Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
https://www.zacks.com/stock/news/2253861/will-novavax-s-nvax-strategic-reshaping-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253861
Apr 11, 2024 - To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
0
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
https://www.zacks.com/stock/news/2253860/will-pfizer-s-pfe-new-drugs-provide-a-boost-to-2024-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253860
Apr 11, 2024 - Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
0